Antimicrobial stewardship in critical care units

Antimicrobial stewardship in critical care units

3 April @ 11.00 CET

Join ISAC president Prof. Souha Kanj and three renowned international experts as they explore cutting-edge strategies to optimize antimicrobial use in ICUs.
Gain insights on balancing effective treatment with resistance prevention in high-risk settings. A must-attend for infectious disease specialists, intensivists and pharmacists.
Enhance your stewardship practices and improve patient outcomes.

Speaker bios

1. Influencing beyond your authority: AMS in critical care patients

Dr Jeroen Schouten is internist and intensivist and a senior researcher at Radboudumc in Nijmegen, the Netherlands. Jeroen Schouten earned a PhD in Infectious Diseases and Implementation Science and has been involved in qualitative research with a focus on antimicrobial stewardship ever since. As senior researcher, he has performed numerous studies on understanding and improving hospital antimicrobial use. He is experienced in qualitative and quantitative research methods and has been involved in many (inter)national initiatives to improve antibiotic prescribing (e.g. ESCMID, ECDC, ISAC, WHO). He heads the Radboudumc Antimicrobial Stewardship Program (ASP) and is course director of the Dutch Masterclass for Antimicrobial Stewardship and Expert consultancy, an International program that focuses on the step wise implementation of AMS activities in healthcare institutions. (www.dutchAMS.com)

He is currently chair at ESGAP (ESCMID Study Group of Antimicrobial Stewardship) and coordinates the ESCMID Certificate European Training Program for Antimicrobial Stewardship. He is also member of the Executive Committee at APUA

2. Antibiotic de-escalation in the ICU: is it worth it?

Prof. Hakan Erdem became a practitioner after graduating from GATA medical faculty in 1993 and worked as a general practitioner between 1994 and 1996. He performed his fellowship at GATA Haydarpasa Training Hospital, Department of Infectious Diseases and Clinical Microbiology in Istanbul during 1996-2000. He worked as an infectious diseases specialist at Sivas Hospital during 2000-2003 and became an assistant professor in Gulhane Academy in 2003, and an associate professor in 2006. I founded the Infectious Diseases International Research Initiative (ID-IRI), a global clinical research platform on infectious diseases and related disciplines in 2008. He was the chief of the Infectious Diseases and Clinical Microbiology Department at GATA Haydarpasa Hospital in Istanbul between July 2014 and July 2015. He received full professorship in 2015 and has worked at various positions since then.

3. Pause or continue: treatment options for antibacterial agents

Dr Roger Bruggemann is associate professor in clinical pharmacology of anti-infectives.

He is responsible for the translational pharmacological research on antifungal drugs. His work involves three domains ranging from in vitro and animal research to trials in humans with strong national and international collaborations.

Roger’s research involves the pharmacological research in special patient populations (paediatrics, ICU, obese, patients with Viral Associated Fungal Infections) and PK-PD behaviour of (novel) antifungal drugs and factors that impact this.

He is board member of the Center of Expertise in Mycology Radboudumc/CWZ, fellow of the European Confederation of Medical Mycology and a member of numerous international societies. Roger has helped draft multiple international guidelines for management of patients with fungal disease.